anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: In singleton pregnancies, the use of cell-free DNA (cfDNA) analysis as a screening test for common fetal trisomies has spread worldwide though we still lack sufficient data for its use in triplet pregnancies. The objective of this study is to assess the performance of cfDNA testing in detecting fetal aneuploidies in triplet pregnancies as a first-tier test.
METHOD: We performed a retrospective cohort study including data from pregnant women with a triplet pregnancy who underwent cfDNA testing between May 1, 2017, and January 15, 2020. cfDNA was obtained by massive parallel sequencing (VeriSeq NIPT solution; Illumina®). The objectives of the study were to assess the diagnostic performance of cfDNA testing for trisomy 21 (T21) (primary outcome), trisomy 18 (T18) and 13 (secondary outcomes).
RESULTS: During the study period, cfDNA testing was performed in 255 women with triplet pregnancy, of which 165 (64.7%) had a neonatal outcome available. Three tests were positive for T21, one of which was confirmed by an antenatal karyotype, and the other was confirmed at birth. The third case did not undergo an invasive procedure and was not confirmed at birth (false positive). In one case, cfDNA testing was positive for T18 and was confirmed by an antenatal karyotype. There were no cases of trisomy 13 in the cohort. The no-call rate was 2.4% at first sampling. Fifty-eight (22.7%) women had embryo reduction, which in 40 (69%) of whom was performed after the cfDNA test result.
CONCLUSION: cfDNA testing could be offered as primary screening for main fetal aneuploidies in triplet pregnancies after provision of appropriate patient information.
NEW MATERIAL:A compound shown by the formula I (R is 1-6C alkyl; R1 is cyclohexyl or a group shown by the formula II), its intermidiate shown by the formula III or IV, or their acid adducts usable as medicines. EXAMPLE:9-(2-cyclohexenyl)-2-n-propoxy-9H-adenine. USE:A nonadrenaline bronchodilatator having improved bronchodilatation activity, capable of lowering side effects of a blood vessel of the heart and the nerve center. Medicines for asthma, bronchitis, chlonic respirator disease, etc. PROCESS:2,6-dichloropurine is reacted with HgCl2 to give a compound shown by the formula V (M is HgCl, etc), which is condensed with 3-halocyclohexene to prepare a compound shown by the formula VI. This compound is aminated by NH3 to give a compound shown by the formula III, which is reacted with a compound shown by the formula R-O-Na (R is a group shown by the formula II) to prepare the desired compound.
UNLABELLED: Blood cultures are central to the management of patients with sepsis and bloodstream infection. Clinical decisions depend on the timely availability of laboratory information, which, in turn, depends on the optimal laboratory processing of specimens. Discrete event simulation (DES) offers insights into where optimization efforts can be targeted. Here, we generate a detailed process map of blood culture processing within a laboratory and use it to build a simulator. Direct observation of laboratory staff processing blood cultures was used to generate a flowchart of the blood culture laboratory pathway. Retrospective routinely collected data were combined with direct observations to generate probability distributions over the time taken for each event. These data were used to inform the DES model. A sensitivity analysis explored the impact of staff availability on turnaround times. A flowchart of the blood culture pathway was constructed, spanning labeling, incubation, organism identification, and antimicrobial susceptibility testing. Thirteen processes in earlier stages of the pathway, not otherwise captured by routinely collected data, were timed using direct observations. Observations revealed that specimen processing is predominantly batched. Another eight processes were timed using retrospective data. A simulator was built using DES. Sensitivity analysis revealed that specimen progression through the simulation was especially sensitive to laboratory technician availability. Gram stain reporting time was also sensitive to laboratory scientist availability. Our laboratory simulation model has wide-ranging applications for the optimization of laboratory processes and effective implementation of the changes required for faster and more accurate results.
IMPORTANCE: Optimization of laboratory pathways and resource availability has a direct impact on the clinical management of patients with bloodstream infection. This research offers an insight into the laboratory processing of blood cultures at a system level and allows clinical microbiology laboratories to explore the impact of changes to processes and resources.
Participants were to receive a single bolus dose of 1.2 mg/kg rocuronium. Three minutes after the start of the rocuronium administration, they were to receive a single bolus dose of 16.0 mg/kg sugammadex.
The present invention provides an enterosoluble capsule and the preparation method thereof, which can solve problems in the prior art such as the complicated process that can not be used in machine-produced vacant capsule. The invention has the technical proposal that: the enterosoluble capsule comprises solid constituent and moisture. The solid constituent comprises main material and auxiliary material. The main material accounts for 50 to 90 percent of solid constituent in weight percentage. The main material is one or a plurality of mixtures in gelatinum, cellulose or polyose; the auxiliary material comprises modifier and plasticizer. The modifier accounts for 9 to 49 percent of the solid constituent in weight percentage. The plasticizer accounts for 0.1 to 1.0 percent of the solid constituent in weight percentage.
The application of 10-hydroxycamptothecin as a fast antidepressant relates to the technical field of antidepressant medicines, wherein the 10-hydroxycamptothecin is 10-hydroxycamptothecin synthesized chemically or 10-hydroxycamptothecin extracted from natural medicines and plants. The chemical synthesis method comprises the following steps: total synthesis, bioconversion, semisynthesis. The 10-hydroxycamptothecin is derived from the extract of plant camptotheca acuminata. An antidepressant drug, wherein the antidepressant component of the antidepressant drug is 10-hydroxycamptothecin. An antidepressant drug, which is used for treating the depression, the antidepressant is prepared from 10-hydroxycamptothecin. The invention discloses application of 10-hydroxycamptothecin as a fast antidepressant, which is verified by experiments, fully proves the fast antidepressant effect of the 10-hydroxycamptothecin, changes the limitation view of the drug effect of the 10-hydroxycamptothecin in the prior art, overcomes the technical bias, and provides an effective treatment way for patients with depression.
The overall goal of this work is to apply and evaluate novel, noninvasive MRI technologies sensitive to sodium and lymphatic circulation in patients with well-characterized lymphatic disease. The results will clarify mechanisms of lymphatic clearance of tissue sodium, and evaluate novel biomarkers of lymphedema risk, progression, and treatment response. Recent evidence supports that lymphatics regulate interstitial sodium levels. When lymphatic clearance is impaired, hypertonic interstitial sodium results in tissue swelling, skin sodium storage, and poor blood pressure control. When lymphatic clearance is impaired in rodent models of lymphedema, lymph stasis and inflammation ensue, leading to tissue remodeling and fibrosis. These data suggest, but do not confirm, that impaired lymphatic clearance contributes to tissue sodium storage and fibrosis. However, this possibility has not been investigated rigorously owing to a lack of clinically-feasible measurement tools sensitive to sodium and lymphatics in humans. To address these gaps in knowledge, the investigators have developed a noninvasive MR lymphangiography (MRL) approach to quantify lymphatic vasculature in patients with unilateral lymphedema of the upper-extremities. They confirmed lateralized lymph stasis and enlarged lymphatic collector cross-sectional area that reduced following manual lymphatic drainage therapy. In parallel to these studies, the investigators optimized noninvasive sodium 23Na MRI for measurement of tissue sodium content (TSC) in the legs of patients with lymphatic insufficiency due to lipedema. In preliminary data, they demonstrate these methods together for the first time in patients with cancer-related lower-extremity lymphedema (LEL) who display significantly elevated skin TSC compared to controls (24.2±6.8 vs. 14.2±1.8 mmol/L, p\<0.001, effect size Cohen's d=1.2). Evidence of lymphatic impairment on MRL and tissue sodium deposition are differential in patients with increasing disease severity, and modified by lymphatic complete decongestive therapy (CDT), motivating the following hypotheses:

Hypothesis (1): Skin TSC inversely correlates with lymphatic flow velocity; lymphatic flow velocity reduces and TSC increases following LN removal in patients at risk for lymphedema. Hypothesis (2): Skin TSC positively correlates with lymphedema stage; subcutaneous sodium co-localizes with fibrotic tissue in patients with lymphedema and fibrosis. Hypothesis (3): Skin TSC decreases and lymphatic flow velocity increases after CDT in affected limbs with LEL; imaging metrics are reproducible in healthy volunteers. Impact: Results will demonstrate relationships between tissue sodium and lymphatic dysfunction in human disease using noninvasive MRI technologies. This will outline clinically-feasible biomarkers of lymphedema risk, progression, and treatment response which could have significance for future clinical trials that seek to evaluate the impact of emerging lymphatic therapies on tissue sodium storage.
Meloxicam, a selective COX-2 inhibitor, has demonstrated clinical effectiveness in managing inflammation and acute pain. Although available in oral and parenteral formulations such as capsule, tablet, suspension, and solution, frequent administration is necessary to maintain therapeutic efficacy, which can increase adverse effects and patient non-compliance. To address these issues, several sustained drug delivery strategies such as oral, transdermal, transmucosal, injectable, and implantable drug delivery systems have been developed for meloxicam. These sustained drug delivery strategies have the potential to improve the therapeutic efficacy and safety profile of meloxicam, thereby reducing the frequency of dosing and associated gastrointestinal side effects. The choice of drug delivery system will depend on the desired release profile, the target site of inflammation, and the mode of administration. Overall, meloxicam sustained delivery systems offer better patient compliance, and reduce the side effects, thereby improving the clinical applications of this drug. Herein, we discuss in detail different strategies for sustained delivery of meloxicam.
PURPOSE: To obtain the subject new compound having an excellent choline action activity and useful for treating anuresis, dysuria, etc., and further for treating digestive tract function depression, chronic gastritis, atonic cccnstipation, etc. CONSTITUTION: A cyclic quaternary ammonium salt of formula I (R1 is H, methyl; R2 is a 1-6C alkyl; X is a halogen, nitro; Y is an anion; but when R1 is H, X is not 5-chlorine atom). For example, 6-bromo-1,1-dimethyl-2,3- dihydroxy-1H-indolium iodide. The compound of formula I is obtained e.g. by reacting an indoline derivative of formula II with a compound of formula: MeY. The reaction is preferably performed in an organic solvent such as acetone, ethanol, benzene or in the absence of the solvent at -20 to 150 deg.C, preferably 0-100 deg.C.
Ferroptosis is a type of regulated cell death hallmarked by iron-mediated excessive lipid oxidation. Over the past decade since the coining of the term ferroptosis, advances in research have led to the identification of intracellular processes that regulate ferroptosis such as GSH-GPX4 pathway and FSP1-coenzyme Q10/vitamin K pathway. From a disease perspective, the involvement of ferroptosis in pathological conditions including kidney disease has attracted attention. In terms of renal pathophysiology, ferroptosis has been widely investigated for its involvement in ischemia-reperfusion injury, nephrotoxin-induced kidney damage and other renal diseases. Therefore, therapeutic interventions targeting ferroptosis are expected to become a new therapeutic approach for these diseases. However, when considering cell death as a therapeutic target, careful consideration must be given to (i) in which type of cells, (ii) which type of cell death mode, and (iii) in which stage or temporal window of the disease. In the next decade, elucidation of the true involvement of ferroptosis in kidney disease setting in human, and development of clinically applicable and effective therapeutic drugs that target ferroptosis are warranted.
Negative symptoms, which include amotivation, social withdrawal and diminished emotional expression are prominent in youth at clinical high risk (CHR) for psychosis. Negative symptoms lead to significant functional impairment and enduring disability in these youth regardless of subsequent conversion to psychosis. At present, there are no established treatments for negative symptoms. Recent evidence from independent studies, however, suggests two promising novel treatment approaches for negative symptoms, transcranial direct current stimulation (tDCS), and computerized remediation strategies, both of which have revealed significant therapeutic effects on negative symptoms in schizophrenia (SZ). tDCS involves delivery of a low intensity continuous electrical field to the frontal cortex. tDCS is very safe and well tolerated, and is currently being investigated as a treatment for several psychiatric disorders. tDCS is also Health Canada approved for the treatment of major depressive disorder. The primary aim of this randomized controlled trial is to evaluate if tDCS combined with a virtual reality-based computerized remediation (VR), administered three times per week for four weeks, is effective for treating negative symptoms in CHR youth, thereby mitigating the enduring functional disability these symptoms cause.
Pharmaceutical dosage forms which quickly dissolve in H2O are prepd. by freezing a soln. contg. partially hydrolyzed gelatin, drug, and other adjuvants in a mould by passing cooling media over the mould and subliming the solvent to produce a network of the gelating carrying the drug.  Thus, a suspension of 40g oxazepam, 30g mannitol, and 0.5g Tween 80 in 1 l of 3% hydrolyzed gelatin soln. are poured to PVC blister trays in 0.75ml portions and subjected to liq. N2.  The portions in the blister trays are freezedried to give the dosage forms which disintegrate in <2 sec. when taken orally.
PROBLEM TO BE SOLVED: To efficiently produce the subject compound by treating a specific penicillanic acid compound with a metal reagent comprising a mixture or an alloy of copper, cobalt and/or manganese, with iron and/or nickel. SOLUTION: A compound of formula I (R is H, a 1-5C alkyl or the like; X is H or bromine) is treated with a metal reagent comprising a mixture or an alloy of copper and/or cobalt and/or manganese with iron and/or nickel to provide the objective 1,1-dioxopenicillanic acid derivative of formula II and a pharmaceutically acceptable salt thereof. Preferably, the metal reagent comprises the mixture or the alloy of the cobalt and the copper with the nickel, and the proportion of the cobalt and the copper in the mixture or the alloy is 0.05-40% and 0.05-40% respectively. The reaction is preferably carried out under the condition kept to pH 2-6. The solvent is a mixture of water with a polar organic solvent such as ethyl ether. The reaction is carried out at 10-30 deg.C.
Chemotherapy-induced nausea and vomiting (CINV) are frequent and dreaded side effects in cancer treatments. CINV has a major impact on patient's condition and quality of life. Prophylaxis is tailored to patient's profile and the emetogenic level of their chemotherapy. The aim of this study is to update the recommendations for CINV prevention and management in pediatric onco-hematology for use in France, by adapting the guidelines of the Pediatric Oncology Group of Ontario (POGO). Clinical practice guideline adaptation is a recognized method for tailoring existing clinical practice guidelines to local context. A multidisciplinary French-speaking panel was formed to discuss about POGO guideline recommendations for the acute and delayed phases, breakthrough, refractory and anticipatory CINV and the evidence supporting them. Panel members were asked whether they wanted to adopt, modify or reject each of the POGO guideline recommendations. Panel members translated each recommendation and adapted recommendations for an implementation in France. Their acceptance required agreement at least 80 % of panel members. Algorithms and tables were created, listing all the recommendations and providing a better overview for decision-making process adapted to the patient's profile. These recommendations should be reviewed for implementation at French institutions caring for pediatric cancer patients and once implemented, the rates of adherence to recommendations and CINV control should be reported.
Belonging to the technical field of traditional Chinese medicines, the invention relates to a Chinese medicinal composition treating facial nerve paralysis. The Chinese medicinal composition is characterized by being prepared from the following Chinese medicinal raw materials by weight: 1-3 parts of periostracum cicada, 1-2 parts of frankincense, 1-2 parts of myrrh, 1-5 parts of cassia twigs, and 1-5 parts of papayas. The composition can be made into powder and patches. The powder is taken orally, and the patches are pasted at an affected part. Cooperative use of the two can reach a good effect, and overcomes the defect of facial muscle injury in operation therapy or acupuncture therapy. The Chinese medicinal composition has the advantages of rapid effect, obvious treatment effect, good tolerance, low cost, and no toxic or side effect.
An intelligent method and an intelligent system for processing physiological data are provided. The method is operated in a cloud system for implementing a health cloud. A database of the intelligent system stores personalized physiological data collected from various user-end devices, and physiological data transmitted from various medical data sources. A big data is therefore formed. The intelligent system receives continuous physiological data and non-continuous physiological data from each of the user-end devices by a communication circuit. The intelligent system performs big-data analysis to establish a physiological prediction model for predicting various physiological states, and therefore determines a physiological status according to the continuous physiological data or the non-continuous physiological data transmitted from each of the user-end devices. A feedback message is accordingly created and sent to a user in real time.
Venovenous (VV) ECMO is rarely used during decompensated circulatory states. Although VA ECMO is the routine option, VV ECMO may be an option in selected patients. We present a case of pulmonary edema due to acute heart failure in a patient 4- and 12-year post-lung transplantation who received VV ECMO. Using a thoughtful cannulation strategy, VV ECMO, and aggressive ultrafiltration, the patient was successfully decannulated, extubated, and discharged from the hospital. In cardiogenic pulmonary edema, VV ECMO represents an additional, and likely under-utilized tool, especially in patients who are at high risk for ventilator-associated lung injury. Cannula location and size should be given additional consideration to potentially transition to V-AV ECMO configuration if necessary.
Recent studies have documented hyperglycemia, insulin resistance, and glucose intolerance in a seemingly increasing proportion of patients with HIV infection. Other studies have described a variety of syndromes of fat accumulation and fat loss, including abdominal obesity. Although initially attributed specifically to protease inhibitors (PI), these abnormalities also have been observed in antiretroviral-experienced but PI-naive patients. Hyperinsulinemia and abdominal obesity are strong independent risk factors for coronary artery disease. In noninfected patients, metformin and thiazolidinediones have been shown to reduce insulin resistance by different mechanisms and also to reduce visceral adiposity. This study investigates the use of metformin and rosiglitazone, a member of the thiazolidinedione class, in HIV-infected patients with hyperinsulinemia and central fat accumulation.

At study entry, clinical and laboratory assessments are performed. A standard OGTT, with plasma samples drawn over 120 minutes, will be performed for glucose and insulin determinations. After completion of entry evaluations, patients are assigned randomly to 1 of 4 double-blinded treatment arms:

Arm A: Metformin plus rosiglitazone placebo. Arm B: Metformin placebo plus rosiglitazone. Arm C: Metformin plus rosiglitazone. Arm D: Metformin placebo plus rosiglitazone placebo. Patients who are still on study drugs at Week 16 (at either full or reduced dose) are switched to the open-label phase to receive the combination of metformin and rosiglitazone through Week 32. Patients have evaluations at Weeks 2, 4, 8, 12, 16, 18, 20, 24, 28, and 32. \[AS PER AMENDMENT 02/05/02: Evaluations must be performed under fasting conditions.\] Safety indices, fasting insulin and glucose levels, visceral \[AS PER AMENDMENT 02/05/02: and subcutaneous abdominal\] fat are assessed. \[AS PER AMENDMENT 02/05/02: Patients who discontinue study treatment due to pregnancy during the study will have the Week 32 evaluations (except CT and DEXA scans).\] \[AS PER AMENDMENT 02/05/02: A mid-thigh measurement was added to the study as a secondary endpoint to look for changes in extremity subcutaneous fat from therapy with rosiglitazone. Rosiglitazone and other peroxisome proliferator-activated receptor (PPAR) gamma activators increase subcutaneous adipogenesis and may thus increase subcutaneous fat and improve insulin resistance in this way.\]